Hepatobiliary Tumors Tissue Samples Acquisition
NCT04445532 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2023-07-07
Summary
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets.
Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.
Conditions
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Gallbladder Cancer
- Biliary Tract Cancer
- Liver Cancer
- Precancerous Condition
- Benign Hepatobiliary Disease
- Healthy, no Evidence of Disease
Interventions
- OTHER
-
Gene expression analysis
Gene expression analysis
- OTHER
-
Genomic analysis
Genomic analysis
- OTHER
-
Protein expression analysis
Protein expression analysis
- OTHER
-
Proteomic profiling
Proteomic profiling
- OTHER
-
Polymerase chain reaction
Polymerase chain reaction
- OTHER
-
Mass spectrometry
Mass spectrometry
- OTHER
-
Immunohistochemistry
Immunohistochemistry
- OTHER
-
Metabolomics profiling
Metabolomics profiling
- OTHER
-
Methylation and epigenetic analysis
Methylation and epigenetic analysis
- OTHER
-
Liquid biopsy analysis
Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
- OTHER
-
Laboratory biomarker analysis
Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
Sponsors & Collaborators
-
OrigiMed
collaborator INDUSTRY -
GeneCast Biotechnology Co., Ltd.
collaborator INDUSTRY -
YuceBio Technology Co., Ltd.
collaborator UNKNOWN -
Geneplus-Beijing Co. Ltd.
collaborator INDUSTRY -
Peking Union Medical College Hospital
lead OTHER
Principal Investigators
-
Haitao Zhao, MD · Peking Union Medical College Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-10-11
- Primary Completion
- 2025-06-01
- Completion
- 2025-06-01
Countries
- China
Study Locations
More Related Trials
-
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
NCT05237193 ·Status: UNKNOWN
-
Liver and Biliary Tumor Tissue Registry
NCT02917759 ·Status: TERMINATED
-
Liquid Biopsy in Hepatocellular Carcinoma
NCT04111029 ·Status: UNKNOWN
-
The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma
NCT05576571 ·Status: UNKNOWN
-
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
NCT00902902 ·Status: UNKNOWN
-
To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)
NCT00709085 ·Status: UNKNOWN
-
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
NCT05327907 ·Status: UNKNOWN
-
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
NCT06899854 ·Status: RECRUITING
-
Study of Serum Tumor Markers of HBV Associated HCC
NCT05825196 ·Status: NOT_YET_RECRUITING
-
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
NCT06115655 ·Status: RECRUITING
-
UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up
NCT06232538 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
NCT06277531 ·Status: RECRUITING
-
The Surveillance of Hepatocellular Carcinoma
NCT05286099 ·Status: UNKNOWN
-
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
NCT04690972 ·Status: RECRUITING
-
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
NCT03493763 ·Status: UNKNOWN
-
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
NCT06134973 ·Status: RECRUITING
-
Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease
NCT02658786 ·Status: WITHDRAWN
-
Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.
NCT01890291 ·Status: COMPLETED
-
Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
NCT04414956 ·Status: RECRUITING ·Phase: NA
-
Hepatocellular Cancer (HCC) Screening in Zhongshan City
NCT02501980 ·Status: UNKNOWN
-
Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
NCT04258566 ·Status: TERMINATED ·Phase: NA
-
Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours
NCT06729944 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma
NCT02550613 ·Status: UNKNOWN
-
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
NCT02936856 ·Status: UNKNOWN ·Phase: NA
-
Clinical Trial Multi-analyte Blood Test
NCT03694600 ·Status: UNKNOWN